期刊
PHARMACOLOGICAL RESEARCH
卷 157, 期 -, 页码 -出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2020.104800
关键词
Hepatocellular carcinoma; HBV; Sorafenib resistance; Chemokine; CCL22 signaling
资金
- Strategic Priority Research Program of CAS [XDB29040102, XDA12010308]
- National Key Basic Research Program of China [2015CB553705]
- National Natural Science Foundation of China [81522030, 81672464, 31600723, 81730097, 81472282]
- National Key Sci-Tech Special Project of China [2018ZX10302204003]
- Shanghai Education Committee of Shuguang Plan [18SG32]
The HBV-initiated hepatocellular carcinoma (HCC) frequently develops from or accompanies long-term chronic hepatitis, inflammation, and cirrhosis, and has a poor prognosis. Sorafenib, an orally active multi-kinase inhibitor, currently the most common approved drug for first-line systemic treatment of advanced HCC, only improves overall survival of three months, suggesting the need for new therapeutic strategies. In this study, we identified that sorafenib selectively resisted in immune competent C57BL/6 mice but not nude mice. The chemokines CCL22 and CCL17 were upregulated by sorafenib, which elevated dramatically higher in HBV-associated HCC. Mechanically, sorafenib accelerates CCL22 expression via TNF-alpha-RIP1-NF-kappa B signaling pathway. Blocking CCL22 signaling with antagonist C-021 and sorafenib treated in combination can inhibit tumor growth and enhance the antitumor response, whereas no significant differences in tumor burden were observed in nude mice upon addition of C-021. These findings strongly suggest that CCL22 signaling pathway strongly contributes to sorafenib resistance in HBV-associated HCC, indicating a potential therapeutic strategy for immunological chemotherapy complementing first-line agents against HBV-associated HCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据